mtruong34 wrote: I believe placebo group is less

mtruong34 wrote:
I believe placebo group is less than 35%. The cd12 population specifically excludes the sickest of the sick on mechanical ventilation, which would have the highest mortality rate. So the 35% would need to be adjusted for this fact, but by how much, very difficult to tell.

My response:
From our early eIND data on Cytodyn's website it's difficult to derive a death rate for s/c eIND cases treated, but I've read the %deaths were 14 to 15%.
If cd12 excluded the sickest of the sick, it will lower the deaths in both the placebo and in the leronlimab groups, and probably lower the LL group most, because as has been mentioned, nothing short of a divine intervention could save many of the sickest, who have substantial organ damage.

There's been a lot of disussion about deaths beyond 28 days, stating that most placebo folks that are going to die, will die in the first 28 days, so death after 28 days would be more in the LL group.

I thought the option of adding the data of deaths after 28 days and up to 42, was only considered for the interim analsis at 75% enrollment, which Nader refused, anticipating rapid enrollment to fill at 390.